Expression of dnDAP12(Y75A) in PBMCs from LGLL patients reduces their production of chemokines. PBMCs from LGLL patients were infected with recombinant retrovirus as described in panel B and supernatants collected at 24 hours and analyzed for (A) RANTES and (B) IL-8 production by ELISA. Viability of PBMCs was confirmed to be more than 80% at time of ELISA analyses by annexin-V–FITC labeling. ELISA results are shown from 1 representative LGLL patient; PBMCs from 2 other patients were assessed yielding similar results. The mean and SEM of triplicate wells are shown.